1. To evaluate study on whether canakinumab might reduce cardiovascular event rates and improve renal function among post-myocardial infarc patients with chronic kidney disease.
2. To determine clinical significance of study results.
10/11/2018 - 1:00pm to 2:00pm CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Dr. Victoria Vo